Teva Agrees to Buy NuPathe for $144 Million, Outbidding Endo
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. agreed to buy NuPathe Inc. for $144 million, outbidding Endo Health Solutions Inc. to gain NuPathe’s migraine patch.
NuPathe holders will receive $3.65 a share in cash, Teva said today in a statement. The price is 59 percent above NuPathe’s closing level on Dec. 13, the last trading day before Endo said it had agreed to buy the company. NuPathe holders may collect as much as $3.15 a share in additional payments from Teva if the Zecuity migraine treatment meets sales goals.